Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP boosted its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 25.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 401,407 shares of the company’s stock after purchasing an additional 82,675 shares during the quarter. Corvus Pharmaceuticals comprises about 0.2% of GSA Capital Partners LLP’s holdings, making the stock its 25th largest position. GSA Capital Partners LLP owned 0.54% of Corvus Pharmaceuticals worth $2,958,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CRVS. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $49,000. Sender Co & Partners Inc. acquired a new position in Corvus Pharmaceuticals in the second quarter valued at $52,000. ProShare Advisors LLC purchased a new position in Corvus Pharmaceuticals during the second quarter worth about $54,000. Shelton Wealth Management LLC purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter valued at about $101,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Corvus Pharmaceuticals by 20.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 15,488 shares of the company’s stock valued at $62,000 after buying an additional 2,599 shares during the period. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on CRVS shares. Oppenheimer increased their price objective on shares of Corvus Pharmaceuticals from $15.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Barclays upped their price objective on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Mizuho set a $30.00 price objective on Corvus Pharmaceuticals in a research note on Thursday, January 29th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $31.80.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock opened at $18.66 on Tuesday. Corvus Pharmaceuticals, Inc. has a one year low of $2.54 and a one year high of $26.95. The stock’s 50 day moving average price is $12.93 and its 200 day moving average price is $8.96. The firm has a market capitalization of $1.56 billion, a PE ratio of -35.21 and a beta of 0.72.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.